Response of adrenocortical carcinoma liver metastases to hepatic artery infusion floxuridine.

Adrenocortical carcinoma (ACC) is a rare malignancy with an incidence of 1–2 million cases per year. 1 Fassnacht M. Terzolo M. Allolio B. Baudin E. Haak H. Berruti A. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012; 366: 2189-2197 Crossref PubMed Scopus (597) Google Scholar For patients with limited recurrent local or distant metastatic disease, resection is the most effective therapy and is associated with 5-year overall survival (OS) rates of up to 41%. 2 Datrice N.M. Langan R.C. Ripley R.T. Kemp C.D. Steinberg S.M. Wood B.J. et al. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol. 2012; 105: 709-713 Crossref PubMed Scopus (71) Google Scholar However, for patients with advanced ACC not amenable to resection, outcome is typically poor, with low objective response rates (ORR; 14–23%) and median OS (14–25 months) to available chemotherapy regimens including immunotherapy or mitotane with multi-agent cytotoxic chemotherapy. 1 Fassnacht M. Terzolo M. Allolio B. Baudin E. Haak H. Berruti A. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012; 366: 2189-2197 Crossref PubMed Scopus (597) Google Scholar ,3 Raj N. Zheng Y. Kelly V. Katz S.S. Chou J. Do R.K.G. et al. PD-1 blockade in advanced adrenocortical carcinoma. J Clin Oncol. 2020; 38: 71-80 Crossref PubMed Scopus (104) Google Scholar